Continuous Renal Replacement Therapy Market Expected to Reach $2.6 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Continuous Renal Replacement Therapy Market," The Continuous Renal Replacement Therapy Market Size was valued at $1.3 billion in 2021, and is estimated to reach $2.6 billion by 2031, growing at a CAGR of 7.7% from 2022 to 2031.

Continuous renal replacement therapy (CRRT) is a slow and smooth continuous extracorporeal blood purification, which is designed to replicate the depurative function of the kidney. It is usually implemented over 24 hours to several days with an aim of gentle correction of fluid overload and removal of excess uremic toxins. It represents a better modality for the management of severe acute chronic injury.

Continuous Renal Replacement Therapy Market Trends are rise in the incidence of acute kidney injury (AKI) across the world. For instance, according to the International Society of Nephrology (INR), an estimated 13.3 million cases of AKI are registered annually worldwide. This is anticipated to boost the adoption of continuous renal replacement therapy at a rapid rate. With the rapid growth in the geriatric population globally, the prevalence of kidney-related diseases is expected to increase significantly. This, in turn, is expected to propel the growth of the CRRT market at a significant rate during the forecast period.

Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for players in the CRRT market. According to an article published by the Journal of Clinical and Diagnostic Research (JCDR) 2018, in a prospective observational study conducted in 100 critically ill patients In India, AKI was observed in 17.3 cases/1,000 persons. To leverage the significant growth opportunities in emerging countries, players are increasingly focusing on undertaking strategic developments to increase their presence in these markets and tap a large number of customers. Additionally, regulatory policies in the Asia Pacific region are more adaptive and business friendly due to the less-stringent data requirements. This, along with the increasing competition in the mature markets (Europe, Japan, and Australia), will further encourage CRRT product manufacturers to focus on the emerging market.

However, as the population in emerging nations is price-sensitive, they prefer lower-priced products. Although the cost of CRRT in developing countries is high which makes these procedures are still unaffordable for a large portion of the population due to the low purchasing power. This limits the demand and uptake of CRRT in developing as well as developed countries. CRRT is a highly specialized and critical therapy that involves complex nursing care. Properly trained ICU nurses are required for the continuous assessment of indications, ensuring good vascular access, avoiding unnecessary interruptions, and preventing complications in patients during CRRT. However, currently, there is a dearth of registered nurses in ICU settings. Moreover, the complexity associated with CRRT are likely to hinder market growth.

The Continuous Renal Replacement Therapy Market Size was valued at $1.3 billion in 2021, and is estimated to reach $2.6 billion by 2031, growing at a CAGR of 7.7% from 2022 to 2031. The Continuous Renal Replacement Therapy Market is Segmented on the basis of product, modality, age group, and region. Depending on the product, the market is classified into dialysates and replacement fluids, disposables, and CRRT systems. The disposables segment is further classified as hemofilter, bloodline sets and tubes, and other disposables. By modality, the market is classified into continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), and continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). According to age group, the market is segmented into pediatrics, and adults.

Region wise, Continuous Renal Replacement Therapy Market Analysis is done across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

By product, the dialysates and replacement fluids segment generated the highest Continuous Renal Replacement Therapy Market Share in 2021 owing to a rise in the incidence of acute kidney injury.

By modality, the continuous venovenous hemofiltration (CVVH) segment generated the highest revenue in the continuous renal replacement therapy market in 2021, as CVVH can remove large volumes of fluid while avoiding the hypotensive episodes caused by intermittent hemodialysis and its intermittent removal of large volumes of fluid.

By age group, the adult's segment generated the highest revenue in the Continuous Renal Replacement Therapy industry in 2021, owing to various regulatory approvals for the adult CRRT, and a rise in the development of novel products for CRRT. Along with this, the adoption of various growth strategies by various market players is creating lucrative opportunities in the segment.

By region, Asia-Pacific accounted for the largest market share in the Continuous Renal Replacement Therapy industry in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increasing in the number of initiatives along with enhanced investments for the overall R&D of CRRT products. In addition, surge in the focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture potential growth opportunities boosts the growth of the market.

The report provides a comprehensive analysis of the key players that operate in the global continuous renal replacement therapy market. The key companies profiled in the report include Anjue Medical Equipment Co. Ltd., Asahi Kasei Corporation, B. Braun Melsungen AG, Chongqing Shanwaishan Science and Technology Co. Ltd., Cytosorbents, Infomed SA, Medica S.p.A, Medical Components Inc., Medites Pharma spol. s.r.o., Medtronic plc., Nikkiso Co. Ltd., Ningbo Tianyi Medical Devices Co. Ltd., Nipro Corporation, SWS Hemodialysis Care Co. Ltd., Toray Industries Inc., Baxter International Inc., and Fresenius Medical Care AG & Co. KGaA.

Key findings of the study

• On the basis of product, the dialysates and replacement fluids segment held 56.23% share in the global market in 2021.
• On the basis of modality, the continuous venovenous hemofiltration (CVVH) segment held the largest market share in 2021, and is expected to remain dominant throughout the forecast period.
• On the basis of age group, the adult segment held the largest market share in 2021, and is expected to remain dominant throughout the forecast period.
• Region wise, Asia-Pacific is expected to experience the highest market share during the forecast period. This was attributed to increase in number of initiatives along with enhanced investments for the overall R&D of CRRT products. In addition, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture potential growth opportunities boosts the market.